Immunoproteomics to identify tumor-associated antigens eliciting humoral response

Cancer Letters

Volumn 278, Issue 2, 2009, Pages 123-129

  Mou, Zhirong ^a   He, Yujun ^a,b   Wu, Yuzhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

2D Western blotting; Autoantibody; Immunoproteomics; Tumor associated antigen

Indexed keywords

ALPHA ENOLASE; APOPTOSIS INDUCING FACTOR; BETA TUBULIN; CALRETICULIN; CARBONATE DEHYDRATASE I; CREATINE KINASE; CYTOKERATIN 18; CYTOKERATIN 8; DEAD BOX PROTEIN; FATTY ACID BINDING PROTEIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INOSINATE DEHYDROGENASE; LIPOCORTIN 1; LIPOCORTIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MANGANESE SUPEROXIDE DISMUTASE; PEROXIREDOXIN; PEROXIREDOXIN 6; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PSORIASIN; TRANSGELIN; TRIOSEPHOSPHATE ISOMERASE; TUMOR ANTIGEN;

ACUTE LEUKEMIA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLON CANCER; ESOPHAGUS CANCER; GENETIC ANALYSIS; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; SHORT SURVEY; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; NEOPLASMS; PROTEOMICS; ROC CURVE;

EID: 64749110352     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.009     Document Type: Review

References (59)

1. Imafuku J., Omenn G.S., and Hanashi S. Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis. Markers 20 (2004) 149-153
2. Mandelboim O., Berke G., Fridkin M., Feldman M., Eisenstein M., and Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369 (1994) 67-71
3. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., Engelhard V.H., Hunt D.F., and Slingluff Jr. C.L. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264 (1994) 716-719
4. Jager E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jager D., Arand M., Wada H., Noguchi Y., Stockert E., Old L.J., and Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187 (1998) 265-270
5. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G., Schobert I., and Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92 (1995) 11810-11813
6. Lee S.Y., Obata Y., Yoshida M., Stockert E., Williamson B., Jungbluth A.A., Chen Y.T., Old L.J., and Scanlan M.J. Immunomic analysis of human sarcoma. Proc. Natl. Acad. Sci. USA 100 (2003) 2651-2656
7. Jager E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jager D., Arand M., Wada H., Noguchi Y., Stockert E., Old L.J., and Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187 (1998) 265-270
8. Seliger B., and Kellner R. Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics 2 (2002) 1641-1651
9. Omenn G.S. Strategies for plasma proteomics profiling of cancer. Proteomics 6 (2006) 5662-5673
10. Klade C.S., Voss T., Krystek E., Ahorn H., Zatloukal K., Pummer K., and Adolf G.R. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1 (2001) 890-898
11. Lichtenfels R.L., Kellner R., Atkins D., Bukur J., Ackermanna A., Becka J., Brenner W., Melchior S., and Seliger B. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analysis. Biochim. Biophys. Acta 1646 (2003) 21-31
12. Gires O., Münz M., Schaffrik M., Kieu C., Raucha J., Ahlemanna M., Eberle D., Mack B., Wollenberg B., Lang S., Hofmann T., Hammerschmidt W., and Zeidler R. Profile identification of disease-associated humoral antigens using AMID, a novel proteomics-based technology. Cell Mol. Life Sci. 64 (2004) 1198-1207
13. Pedersen S.K., Sloane A.J., Prasad S.S., Sebastian L.T., Lindner R.A., Hsu M., Robinson M., Bye P.T., Weinberger R.P., and Harry J.L. An immunoproteomics approach for identification of clinical biomarkers for monitoring disease. Mol. Cell Proteomics 4 (2005) 1052-1060
14. Madrid F.F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 230 (2005) 187-198
15. Le Naour F., Brichory F., Beretta L., and Hanash S.M. Identification of tumor-associated antigens using proteomics. Technol. Cancer Res. Treat. 1 (2002) 257-262
16. Görg A., Obermaier C., Boguth G., Harder A., Scheibe B., Wildgruber R., and Weiss W. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21 (2000) 1037-1053
17. Canelle L., Bousquet J., Pionneau C., Deneux L., Imam-Sghiouara N., Carona M., and Joubert-Caron R. An efficient proteomics-based approach for the screening of autoantibodies. J. Immunol. Meth. 299 (2005) 77-89
18. Prasannan L., Misek D.E., Hinderer R., Michon J., Geiger J.D., and Hanash S.M. Identification of β-tubulin isoforms as tumor antigens in neuroblastoma. Clin. Cancer Res. 6 (2000) 3949-3956
19. Lichtenfels R., Achermann A., Kellner R., and Seliger B. Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line. Electrophoresis 22 (2001) 1801-1809
20. Caron M., Choquet-Kastylevsky G., and Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol. Cell Proteomics 6 (2007) 1115-1122
21. Horn S., Lueking A., Murphy D., Staudt A., Gutjahr C., K S., Konig A., Landsberger M., Lehrach H., Felix S.B., and Cahill D.J. Profiling humoral autoimmune repertoire of dilated cardiomyopathy (DCM) patients and development of a disease-associated protein chip. Proteomics 6 (2006) 605-613
22. Robinson W.H., Steinman L., and Utz P.J. Protein arrays for autoantibody profiling and fine-specificity mapping. Proteomics 3 (2003) 2077-2084
23. Nam M.J., Madoz-Gurpide J., Wang H., Lescure P., Schmalbach C.E., Zhao R., Misek D.E., Kuick R., Brenner D.E., and Hanash S.M. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 3 (2003) 2108-2115
24. Qin S., Qiu W., Ehrlich J.R., Ferdinand A.S., Richie J.P., O'leary M.P., Lee M.L., and Liu B.C. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 6 (2006) 3199-3209
25. Grus F.H., Joachim S.C., and Pfeiffer N. Analysis of complex autoantibody repertoires by surface-enhanced laser desorption/ionization-time of flight mass spectrometry. Proteomics 3 (2003) 957-961
26. Fujita Y., Nakanishi T., Miyamoto Y., Hiramatsu M., Mabuchi H., Miyamoto A., Shimizu A., Takubo T., and Tanigawa N. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 263 (2008) 280-290
27. Fujita Y., Nakanishi T., Hiramatsu M., Mabuchi H., Miyamoto Y., Miyamoto A., Shimizu A., and Tanigawa N. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin. Cancer Res. 12 (2006) 6415-6420
28. He Y., Wu Y., Mou Z., Li W., Zou L., Fu T., Zhang A., Xiang D., Xiao H., and Wang X. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics-Clin. Appl. 1 (2007) 336-342
29. Brichory F.M., Misek D.E., Yim A.-M., Krause M.C., Giordano T.J., Beer D.G., and Hanash S.M. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. USA 98 (2001) 9824-9829
30. Brichory F., Beer D., Le Naour F., Giordano T., and Hanash S. Proteomics-based identification of protein gene product 95 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 61 (2001) 7908-7912
31. Li C., Xiao Z., Chen Z., Zhang X., Li J., Wu X., Li X., Yi H., Li M., Zhu G., and Liang S. Proteome analysis of human lung squamous carcinoma. Proteomics 6 (2006) 547-558
32. Nakanishi T., Takeuchi T., Ueda K., Murao H., and Shimizu A. Detection of eight antibodies in cancer patients' sera against proteins derived from the adenocarcinoma A549 cell line using proteomics-based analysis. J. Chromatogr. B 838 (2006) 15-20
33. Yang F., Xiao Z.Q., Zhang X.Z., Li C., Zhang P.F., Li M.Y., Chen Y., Zhu G.Q., Sun Y., Liu Y.F., and Chen Z.C. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J. Proteome Res. 6 (2007) 751-758
34. Hong S.-H., Misek D.E., Wang H., Puravs E., Giordano T.J., Greenson J.K., Brenner D.E., Simeone D.M., Logsdon C.D., and Hanash S.M. An autoantibody-mediated immune response to Calreticulin isoforms in pancreatic cancer. Cancer Res. 64 (2004) 5504-5510
35. Xia Q., Kong X.-T., Zhang G.-A., Hou X.-J., Qiang H., and Zhong R.-Q. Proteomics-based identification DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem. Biophys. Res. Commun. 330 (2005) 526-532
36. Tomaino B., Cappello P., Capello M., Fredolini C., Ponzetto A., Novarino A., Ciuffreda L., Bertetto O., De Angelis C., Gaia E., Salacone P., Milella M., Nistico P., Alessio M., Chiarle R., Giuffrida M.G., Giovarelli M., and Novelli F. Autoantibody signature in human ductal pancreatic adenocarcinoma. J. Proteome Res. 6 (2007) 4025-4031
37. Le Naour F., Brichory F., Misek D.E., Bréchot C., Hanash S.M., and Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol. Cell. Proteomics 1 (2002) 197-203
38. Takashima M., Kuramitsu Y., Yokoyama Y., Lizuka N., Harada T., Fujimoto M., Sakaida I., Okita K., Oka M., and Nakamura K. Proteomics analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics 6 (2006) 3894-3900
39. Li L., Chen S.-H., Yu C.-H., Li Y.-M., and Wang S.-Q. Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J. Proteome Res. 7 (2008) 611-620
40. Kellner R., Lichtenfels R., Atkins D., Bukur J., Ackermannm A., Beck J., and Seliger B. Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2 (2002) 1743-1751
41. Unwin R.D., Harnden P., Pappin D., Rahman P., Whelan P., Craven R.A., Selby P.J., and Banks R.E. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3 (2003) 45-55
42. Le Naour F., Misek D.E., Krause M.C., Deneux L., Giordano T.J., Scholl S., and Hanash S.M. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin. Cancer Res. 7 (2001) 3328-3335
43. Shin B.K., Wang H., and Hanash S. Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J. Mammary Gland Biol. Neoplasia 7 (2002) 407-413
44. Philip R., Murthy S., Krakover J., Sinnathamby G., Zerfass J., Keller L., and Philip M. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J. Proteome Res. 6 (2007) 2509-2517
45. Gagnon A., Kim J.H., Schorge J.O., Ye B., Liu B., Hasselblatt K., Welch W.R., Bandera C.A., and Mok S.C. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin. Cancer Res. 14 (2008) 764-771
46. Rauch J., Ahlemann M., Schaffrik M., Mack B., Ertongur S., Andratschke M., Zeidler R., Lang S., and Gires O. Allogenic antibody-mediated identification of head and neck cancer antigens. Biochem. Biophys. Res. Commun. 323 (2004) 156-162
47. Zou L., Wu Y., Pei L., Zhong D., Gen M., Zhao T., Wu J., Ni B., Mou Z., Han J., Chen Y., and Zhi Y. Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leukoc. Res. 29 (2005) 1387-1391
48. Cui J.W., Li W.-H., Wang J., Li A.-L., Li H.-Y., Wang H.-X., He K., Li W., Kang L.H., Yu M., Shen B.F., Wang G.J., and Zhang X.M. Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol. Cell. Proteomics 4 (2005) 1718-1724
49. Ueda K., Nakanishi T., Shimizu A., Takubo T., and Matsuura N. Identification of l-plastin autoantibody in plasma of patients with non-Hodgkin's lymphoma using a proteomics-based analysis. Ann. Clin. Biochem. 45 (2008) 65-69
50. Cappello F., Ribbene A., Campanella C., Czarnecka A.M., Anzalone R., Bucchieri F., Palma A., and Zummo G. The value of immunohistochemical research on PCNA, p53 and heat shock proteins in prostate cancer management: a review. Eur. J. Histochem. 50 (2006) 25-34
51. Czarnecka A.M., Campanella C., Zummo G., and Cappello F. Mitochondrial chaperones in cancer: from molecular biology to clinical diagnostics. Cancer Biol. Ther. 5 (2006) 714-720
52. Castle P.E., Ashfaq R., Ansari F., and Muller C.Y. Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett. 229 (2005) 245-252
53. Faried A., Sohda M., Nakajima M., Miyazaki T., Kato H., and Kuwano H. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur. J. Cancer 40 (2004) 2804-2811
54. Cappello F., Rappa F., David S., Anzalone R., and Zummo G. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis 23 (2003) 1325-1331
55. Zolg W. The proteomics search for diagnostic biomarkers: lost in translation?. Mol. Cell. Proteomics 5 (2006) 1720-1726
56. Li W.-H., Zhao J., Li H.-Y., Liu H., Li A.-L., Wang H.-X., Wang J., He K., Liang B., Yu M., Shen B.F., and Zhang X.M. Proteomics-based identification of autoantibodies in the sera of healthy Chinese individuals from Beijing. Proteomics 6 (2006) 4781-4789
57. Hanash S.M., Pitteri S.J., and Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 452 (2008) 571-579
58. Zweig M.H., and Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39 (1993) 561-577
59. Finn O.J. Immune response as a biomarker for cancer detection and a lot more. N. Engl. J. Med. 353 (2005) 1288-1290